LFWD — Lifeward Ltd.

Summary of Lifeward Ltd. Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q3 2025 revenue was $6.2 million, a slight increase of 1.1% year-over-year from $6.1 million in Q3 2024, and an 8% increase from Q2 2025's $5.7 million.
• Product Breakdown: Revenue from traditional products (ReWalk, MyoCycle, ReStore) increased to $3.1 million (up 24% from $2.5 million in Q3 2024). Revenue from ATLAS G products decreased to $3.1 million from $3.6 million year-over-year.
• Gross Profit: GAAP gross profit was $2.7 million (43.7% of revenue), compared to $2.2 million (36.2% of revenue) in 2024.
• Operating Loss: GAAP operating loss was $3.1 million, slightly improved from $3.2 million in Q3 2024. Non-GAAP operating loss reduced to $3 million from $4.1 million.
• Cash Position: Ended Q3 with $2 million in cash and cash equivalents, having secured a $3 million loan from Oramed to enhance liquidity.

2. Strategic Updates and Business Highlights

• Leadership under CEO William Mark Grant has focused on rebuilding operational fundamentals, enhancing efficiency, and improving the commercial model.
• Achieved record placements of ReWalk units for Medicare beneficiaries, marking a second consecutive record since the CMS fee schedule was established in April 2024.
• Expanded patient access with the first Medicare Advantage commercial revenue for the ReWalk 7 exoskeleton and received CE Mark approval for European market entry.
• Operational efficiencies led to a 16% reduction in cash burn and a 27% decrease in non-GAAP operating loss compared to the previous year.

3. Forward Guidance and Outlook

• Lifeward Ltd. reaffirmed its full-year 2025 revenue guidance of $24 million to $26 million, indicating expected growth of approximately 21% from Q3 figures.
• Projected non-GAAP net loss for 2025 is expected to be in the range of $12 million to $14 million.
• Confidence in achieving guidance is supported by a strong backlog and healthy commercial pipeline.

4. Bad News, Challenges, or Points of Concern

• Revenue from the ATLAS G product line declined by 15% year-over-year, raising concerns about its market performance.
• The company faces challenges in scaling operations effectively to meet growth demands and ensuring consistent sales performance across different product lines.
• There is a need for ongoing assessment and adjustment of sales strategies, particularly in the U.S. market, where focus has shifted to bifurcated sales teams for different product lines.

5. Notable Q&A Insights

• The company has 33 active ReWalk rentals in Germany, which are expected to convert to sales within three to six months.
• The partnership with CoreLife is progressing well, with expectations for pipeline growth.
• Medicare accounts for approximately 50% of ReWalk product revenue, highlighting the importance of this payer in the overall sales strategy.
• The management expressed optimism about the turnaround potential of the company, emphasizing the importance of establishing solid fundamentals and leveraging strategic partnerships for future growth.

Overall, Lifeward Ltd. is making strides in operational efficiency and market access, but it faces challenges in certain product lines and must navigate the complexities of scaling its business effectively.